Increlex Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing diagnosis of IGF-1 deficiency, expansion of pediatric endocrinology services, approval of recombinant growth factor therapies, improved growth disorder screening programs, rising awareness among healthcare providers.

The growth in the forecast period can be attributed to expansion of personalized pediatric growth treatments, rising investments in rare disease therapies, increasing adoption of digital growth monitoring tools, growing focus on long-term pediatric outcome optimization, advancement in recombinant protein manufacturing. Major trends in the forecast period include increasing adoption of recombinant growth therapies, rising focus on pediatric endocrine disorders, expansion of precision dosing protocols, improved early diagnosis of growth disorders, enhanced long-term growth monitoring.

The increasing prevalence of childhood-onset growth hormone deficiency (CGHD) is expected to drive the growth of the Increlex market going forward. Childhood-onset growth hormone deficiency occurs when the body produces insufficient growth hormone during childhood, resulting in delayed growth and reduced height. The rise in CGHD prevalence is largely attributed to advancements in diagnostic techniques and increased awareness of the condition. Greater recognition and earlier diagnosis of CGHD are boosting demand for Increlex, a synthetic insulin-like growth factor-1 (IGF-1) therapy, as more affected children receive appropriate treatment. For example, in November 2023, according to the Council of Health Insurance, a Saudi Arabia-based government office responsible for regulatory decisions, CGHD was estimated to affect between 1 in 3,500 and 1 in 10,000 children, with a higher occurrence observed in boys. Therefore, the rising prevalence of childhood-onset growth hormone deficiency is contributing to the growth of the Increlex market.

The increase in healthcare expenditure is also expected to propel the growth of the Increlex market going forward. Healthcare expenditure refers to the total spending on healthcare services, including medical treatments, medications, and hospital care, over a given period. Healthcare spending is increasing due to factors such as population aging, rising healthcare needs, technological advancements in medicine, and higher costs for services and pharmaceuticals. Higher healthcare expenditure supports the growth of the Increlex market by improving access to advanced therapies for conditions such as childhood-onset growth hormone deficiency. For instance, in November 2025, according to the Organisation for Economic Co-operation and Development, a France-based intergovernmental organization, average health spending across OECD countries in 2024 was estimated at nearly USD 6,000 per capita after adjusting for purchasing power differences, with the United States being the highest spender. Therefore, rising healthcare expenditure is driving the growth of the Increlex market.

In October 2024, Eton Pharmaceuticals Inc., a US-based pharmaceutical company, acquired Increlex (mecasermin injection) from Ipsen S.A. for an undisclosed amount. Under the agreement, Ipsen will continue distributing Increlex for six months before Eton assumes global commercialization responsibilities. This acquisition enables Eton to expand its product portfolio while ensuring uninterrupted access to Increlex for patients. Ipsen S.A. is a France-based pharmaceutical company involved in drug development, including Increlex.

Major companies operating in the increlex market are Ipsen S.A.

North America was the largest region in the increlex market in 2025. The regions covered in the increlex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the increlex market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the increlex market by increasing costs of imported recombinant protein production inputs, formulation materials, sterile packaging components, and cold-chain logistics infrastructure. Pediatric healthcare providers in North America and Europe are most affected due to reliance on global biologics manufacturing networks, while Asia-Pacific faces export cost pressures. These tariffs are contributing to higher therapy costs and access challenges. However, they are also supporting localized biologics manufacturing, regional production scale-up, and strengthened supply chains for pediatric endocrine treatments.

The increlex market research report is one of a series of new reports that provides increlex market statistics, including increlex industry global market size, regional shares, competitors with a increlex market share, detailed increlex market segments, market trends and opportunities, and any further data you may need to thrive in the increlex industry. This increlex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Increlex is the brand name for mecasermin, a recombinant human insulin-like growth factor-1 (rhIGF-1). It is used to treat growth failure in children with severe primary IGF-1 deficiency or in those whose bodies do not produce adequate levels of insulin-like growth factor-1, which is essential for normal growth.

The primary age groups for Increlex include infants, toddlers, and children aged 5 to 12 years. Pediatric patients include children diagnosed with severe primary IGF-1 deficiency (SPIGFD), a rare growth disorder in which the body has insufficient insulin-like growth factor-1 despite normal growth hormone levels. Increlex (mecasermin) addresses this deficiency by mimicking IGF-1, thereby improving growth rates and supporting overall developmental outcomes. It is distributed through hospitals, specialty clinics, online pharmacies, and retail pharmacies and is used for growth hormone deficiency and other related applications.

The increlex market consists of sales of increlex injectable solution, increlex pre-filled syringes, and increlex vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.